SEC Form 4 · accession 0001179110-18-008611
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Albright
Officer — Chief Scientific Officer
Period of report
Jun 13, 2018
Accepted (ET)
Jun 15, 2018 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 13, 2018 | M | 10,000 | $16.51 | A | 10,000 | D | |
| Common StockF2 | Jun 13, 2018 | S | 10,000 | $35.98 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $16.51 | Jun 13, 2018 | M | 10,000 | D | — | Sep 8, 2026 | Common Stock | 10,000 | 205,000 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $35.62 to $36.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020.